http://www.epo.org/service-support/availability-of-online-services/2022/20220715.html
Content reproduced from the Website of the European Patent Office as permitted by their terms of use.
The
EPO is aware of a malfunction in the WIPO Sequence 2.1.1. tool for creating
sequence listings compliant with WIPO Standard ST.26. The technical malfunction
can lead to the deletion of the entire feature table for a particular SEQ ID.
The malfunction appears to occur upon generation of the sequence listing.
Therefore, applicants are strongly recommended to also validate each sequence
listing using the ‘Validate Sequence Listing’ function of WIPO Sequence after
generating the sequence listing and before uploading them in the filing tool.
If no error message is displayed during this second validation this should
allow applicants to exclude that the malfunction has occurred.
- If an error message is displayed
during the second validation and a sequence listing has been effected by the
technical malfunction, with the consequence that the feature table for a SEQ ID
has been deleted, the issue may be resolved as follows: - Go to WIPO Sequence software and
press on ‘Import sequence listing’. - Give a different name to the
project so that you will be able to find it back in the list of projects. - Check the boxes to import all
general information part and all sequences. - Once the sequence listing has
been imported, navigate to the sequence that has the error. - You will notice that the
qualifiers mol_type and organism of the ‘source’ feature are blank, i.e., they
contain no data. - Add the correct data to the
qualifiers mol_type and organism as you did in the initial project. - Add any other feature (if
applicable). - Validate the project.
- Generate the sequence listing.
- Validate the sequence listing by
using ‘Validate Sequence Listing’ function of WIPO Sequence. - This time there should be NO
error about a missing feature table for the given sequence.
Applicants
are also strongly recommended not to delete the project files for sequence
listings.
We
apologise for any inconvenience. Please always refer to
the title of this notice when addressing the EPO in relation to this issue.